One patient with advanced lung adenocarcinoma developed refractory hypertension after 19 months of treatment with bevacizumab and afatinib,the clinical pharmacist analyzed the patient's medication,and consulted the relevant literature,considering that the patient's refractory hypertension was related to bevacizumab and sleep difficulties.Because of the patient's proteinuria and the fact that the patient's blood pressure was not controlled below 130/80 mmHg,it was recommended that bevacizumab should be suspended,and the doctor accepted the recommendation.Through multiple adjustments to the antihypertensive regimen(nifedipine controlled-release,sacubitril/valsartan,metoprolol,indapamide)and sleep improvement(mirtazapine,lorazepam).The patient's sleep duration was extended to 4-5 hours,blood pressure was controlled below 130/80 mmHg,and bevacizumab treatment was resumed.In this case,the clinical pharmacist participated in the patient's drug treatment process,assisted the doctor in the adjustment of the individualized treatment plan for special populations,and promoted the patient's rational drug use.

One patient with advanced lung adenocarcinoma developed refractory hypertension after 19 months of treatment with bevacizumab and afatinib,the clinical pharmacist analyzed the patient's medication,and consulted the relevant literature,considering that the patient's refractory hypertension was related to bevacizumab and sleep difficulties.Because of the patient's proteinuria and the fact that the patient's blood pressure was not controlled below 130/80 mmHg,it was recommended that bevacizumab should be suspended,and the doctor accepted the recommendation.Through multiple adjustments to the antihypertensive regimen(nifedipine controlled-release,sacubitril/valsartan,metoprolol,indapamide)and sleep improvement(mirtazapine,lorazepam).The patient's sleep duration was extended to 4-5 hours,blood pressure was controlled below 130/80 mmHg,and bevacizumab treatment was resumed.In this case,the clinical pharmacist participated in the patient's drug treatment process,assisted the doctor in the adjustment of the individualized treatment plan for special populations,and promoted the patient's rational drug use.

Objective To develop an overall health risk model and to evaluate its convergent validity and reliability.Methods Health examination results of 230 adults from a public institution were collected by using Chinese Health Risk Appraisal Questionnaire V1.0 (CHRAQ V1.0).An CHRAQ V1.0-based overall health risk model was then developed,which included 34 items.Kolmogorov-Smirnov was used to test normal distribution of the data.Pearson correlation coefficient and Spearman correlation coefficient were used to evaluate parallel validity of the model.Crane Bach coefficient,Spearman-Brown coefficient and test-retest reliability were calculated to evaluated the reliability of the model.Results In this study,212 valid questionnaires (92.17％) were received.The average score of the newly developed overall health risk model was 41.96 ± 9.69,and its kurtosis coefficient and coefficient of skewness were 2.105 and 0.862,respectively.In Kolmogorov-Smirnov,the data were normally distributed (Z =1.073,P =0.199).The correlation coefficient of positive rate of all objective examinations with model scores was 0.774 (P ＜ 0.05).The Cronbach's alpha coefficient,Spearman-Brown coefficient and test-retest reliability of the model were 0.652,0.784 and 0.841,respectively (P ＜ 0.05).Conclusion In this investigation,our newly developed overall health risk model shows good validity and reliability and application prospect in the field of health management.

Objective To know the effects of laver intake on arsenic species in urine of people, and investigate the characteristics of arsenic metabolism. Methods The urine samples were collected from 24 subjects who had laver available on markets, arsenic species in urine samples were detected with hydride generation atomic fluorescence spectroscopy. Results There was a significant increase of urinary iAs seventy-two hours after laver intake except one and forty-eight hours, increase of MMA seventy-two hours after laver intake except one and twelve hours, and increase of DMA from the first hour to the 72nd hour in male group. There was a significant increase in the urinary iAs seventy-two hours after laver intake except three, five and forty-eight hours, increase of MMA seventy-two hours after laver intake except five and twelve hours, increase of DMA from one to seventy-two hours after laver intake in female group. Conclusion The urinary concentration of DMA is significantly higher in female group compared with male group after laver intake in the same weight and urinary DMA increases in the beginning, after that decreases gradually.